Evidence map›Paper›PMID 41457248›Full record

ArticleVirology journal2025

The isolation and characterisation of a temperate phage ɸPh_AJ01 against Acinetobacter junii.

Niti Sarat, Amrita Salim, Sindhu K Shetty, Sanjay Pal, Kajal Kamboj, Daizee Talukdar, Bhabatosh Das, Bipin G Nair, Ajith Madhavan

Abstract read
In one paragraph

Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Niti SaratAmrita School of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri Campus, Kollam, 690525, India.
Amrita SalimDepartment of Medical Biochemistry and Biophysics, Umeå University, Umeå, 90187, Sweden.
Sindhu K ShettyAmrita School of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri Campus, Kollam, 690525, India.
Sanjay PalAmrita School of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri Campus, Kollam, 690525, India. sanjaypal@am.amrita.edu.ORCID http://orcid.org/0000-0002-2012-0734
Kajal KambojFunctional Genomics Laboratory, BRIC-Translational Health Science and Technology Institute, Faridabad, 121001, India.
Daizee TalukdarFunctional Genomics Laboratory, BRIC-Translational Health Science and Technology Institute, Faridabad, 121001, India.
Bhabatosh DasFunctional Genomics Laboratory, BRIC-Translational Health Science and Technology Institute, Faridabad, 121001, India.
Bipin G NairAmrita School of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri Campus, Kollam, 690525, India.
Ajith MadhavanAmrita School of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri Campus, Kollam, 690525, India. ajithm@am.amrita.edu.ORCID http://orcid.org/0000-0002-4519-0851

Funding

Amrita Vishwa Vidyapeetham University ASG2022094
6 · The paper itself

Abstract

backgroundAcinetobacter junii is an emerging opportunistic human and animal pathogen, fast gaining antimicrobial resistance. As conventional treatment becomes ineffective, alternatives are needed to address this challenge. Bacteriophages offer a promising yet underexplored solution in combating A. junii infections. Here, we report the isolation and characterisation of a temperate phage, ɸPh_AJ01, effective against a carbapenem-resistant A. junii. Moreover, the study adopts a technique for biasing the temperate phage to the lytic life cycle to address the issues of lysogeny. The efficacy of the phage in rescuing A. junii-infected Caenorhabditis elegans is also demonstrated.

methodsPhage ɸPh_AJ01 was isolated and purified from the Cooum River in Chennai, India. Host range analysis, adsorption assay, growth curve, and in vitro bacteriolytic test were performed. Transmission electron microscopy and whole-genome sequencing were carried out to understand its morphological and genetic features. Phage stability was tested in different temperatures and pH conditions. Antibiofilm activity of the phage was studied using inhibition and disruption assays. Bacteriophage-insensitive mutation frequency of A. junii was evaluated by the patch screen test. Experiment to bias the temperate phage towards lytic life cycle and, survival assay with A. junii-infected C. elegans were also performed.

resultsɸPh_AJ01 is a temperate, narrow-spectrum, icosahedral, tailed phage that efficiently infected A. junii, yielding a burst size of 74 ± 8 virions per cell with good temperature and pH stability. ɸPh_AJ01 inhibited biofilm formation by 92%, and disruption by 73.8%. A. junii gained resistance to ɸPh_AJ01 at a frequency of 6.88E-06 CFU/mL. The double-stranded DNA genome of 44,561 bp and GC content of 38.62%, encodes 65 open reading frames. The phage is novel, with only 80% similarity to other Acinetobacter phages. The genome is devoid of antibiotic-resistant and virulence genes. The temperate phage, when biased with ciprofloxacin (50 ng/mL), resulted in ≥ 5 log reduction of A. junii, with an associated 6-log reduction in lysogens and 5-fold increase in phage titre. The in vivo study yielded a 65% increase in survival of A. junii-infected C. elegans with the phage and ciprofloxacin when compared to 28% with phage alone.

conclusionsThe study describes the isolation and characterisation of a temperate phage ɸPh_AJ01 against A. junii. A lysogeny biasing strategy was additionally evaluated under both in vitro and in vivo conditions to address the limitations of the temperate phage.

Indexed as

AcinetobacterBacteriophagesAcinetobacter InfectionsAnimalsBiofilmsCaenorhabditis elegansGenome, ViralHost SpecificityIndiaLysogenyPhage TherapyAcinetobacter juniiBacteriophageEmerging infectionOpportunistic pathogen

Identifiers

PMID41457248
PMCPMC12958538

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.